Company Overview

Evotec SE is a Germany-based biotechnology company focused on drug discovery, preclinical development, and manufacturing services for pharmaceutical, biotechnology, and academic partners. The company operates within the life sciences and biopharmaceutical industries, providing integrated research platforms that support the development of therapeutics across areas including neuroscience, oncology, metabolic diseases, infectious diseases, immunology, fibrosis, and rare diseases. Evotec’s business model combines fee-for-service research, long-term strategic partnerships, milestone payments, royalties, and shared intellectual property participation.

The company’s primary revenue drivers are its discovery and development collaborations, platform-based research services, and biologics manufacturing activities. Through its evolution from a technology-driven discovery company founded in 1993 in Hamburg, Evotec expanded into a broader drug development and biotechnology platform through acquisitions, alliances, and investments in precision medicine and biologics capabilities. Its strategic positioning is built around large-scale scientific infrastructure, data-driven drug discovery, induced pluripotent stem cell (iPSC) technologies, and long-term collaborations with major pharmaceutical companies.

Business Operations

Evotec operates primarily through two core business areas: Shared R&D and Just – Evotec Biologics. The Shared R&D segment provides integrated drug discovery and development services through collaborative partnerships with pharmaceutical and biotechnology companies. This segment generates revenue from research payments, milestones, licensing arrangements, and royalty participation tied to partnered programs. The Just – Evotec Biologics business focuses on biologics development and manufacturing, including continuous manufacturing technologies and contract development and manufacturing organization (CDMO) services for biologic therapeutics.

The company maintains operations across Europe, North America, and Asia, with research and production facilities in Germany, France, Italy, the United Kingdom, the United States, and other markets. Evotec controls proprietary technology platforms in computational chemistry, high-throughput screening, cell therapy, biologics engineering, and iPSC-based disease modeling. Major strategic collaborations have included partnerships with Bristol Myers Squibb, Bayer, Novo Nordisk, Takeda, Boehringer Ingelheim, and the U.S. Department of Defense. Key subsidiaries and acquired entities include Just – Evotec Biologics, Cyprotex, and Aptuit, which expanded the company’s preclinical, toxicology, and drug development capabilities.

Strategic Position & Investments

Evotec’s strategic direction has focused on becoming an integrated end-to-end drug discovery and development partner while expanding higher-margin platform technologies and biologics manufacturing. The company has invested heavily in precision medicine, AI-enabled discovery workflows, cell therapy infrastructure, and biologics manufacturing capacity in the United States and Europe. Its strategy also emphasizes long-duration alliances with large pharmaceutical companies that share both development risk and downstream economics.

Major acquisitions have included Aptuit in 2017, which significantly expanded Evotec’s chemistry and development services, and Just Biotherapeutics in 2019, which formed the foundation for Just – Evotec Biologics. The company has also invested in neuroscience, pandemic preparedness, gene therapy, and protein degradation research initiatives. Evotec has participated in public-private collaborations and government-backed initiatives related to infectious disease preparedness and biologics manufacturing scalability, particularly in partnership with U.S. federal agencies.

Geographic Footprint

Evotec is headquartered in Hamburg, Germany, and maintains a substantial operational footprint across Europe, North America, and selected locations in Asia. The company operates research, discovery, and manufacturing facilities in countries including Germany, France, Italy, the United Kingdom, and the United States. Its U.S. presence expanded significantly following the acquisition of Just Biotherapeutics, with biologics manufacturing operations in Washington State and additional investments in large-scale biologics infrastructure.

The company serves a global customer base composed primarily of pharmaceutical companies, biotechnology firms, academic institutions, and public-sector organizations. Evotec’s international influence is reinforced through cross-border research partnerships, multinational licensing agreements, and participation in global therapeutic development programs. Its collaborative model enables integration into drug development pipelines across multiple continents, particularly in the United States, Europe, and key pharmaceutical research hubs.

Leadership & Governance

Evotec has historically operated under a science-driven and partnership-oriented leadership philosophy centered on collaborative innovation, scalable technology platforms, and diversified therapeutic exposure. Founder involvement helped shape the company’s early technology focus, while later leadership emphasized expansion into integrated discovery and biologics manufacturing. The company is governed under the German corporate governance framework with both management and supervisory board oversight structures.

Key executives and leadership figures include:

• Christian Wojczewski – Chief Executive Officer
• Enno Spillner – Chief Financial Officer
• Dr. Cord Dohrmann – Chief Scientific Officer
• Dr. Craig Johnstone – Chief Operating Officer, Just – Evotec Biologics
• Dr. Mario Polywka – Former Chief Operating Officer and long-serving executive leader
• Dr. Werner Lanthaler – Former Chief Executive Officer

Leadership strategy has emphasized long-term research alliances, scientific scalability, diversified revenue streams, and expansion of proprietary platforms that support both small-molecule and biologics drug development.